Cellectis S.A. ADR (CLLS)

$1.72 0.05 (2.99%)

15:59 EDT CLLS Stock Quote Delayed 30 Minutes

7 CRISPR Stocks With the Best Long-Term Potential

By Alex Sirois, InvestorPlace Contributor Jan 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

7 Gene Editing Stocks Promising to Change our DNA

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Volume:

Previous Close -

Market Cap 78.23M

PE Ratio -

EPS -

Volume (Avg. Vol.) 62,490

Day's Range $1.65 - $1.75

52-Week Range $1.58 - $4.04

Dividend & Yield N/A (N/A)

CLLS Stock Predictions, Articles, and Cellectis S.A. ADR News

From InvestorPlace
From the Web

Investing in CRISPR Stocks: Ultimate Genetic Editing Guide

By Luke Lango, InvestorPlace Senior Investment Analyst Jul 5, 2021

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century

By Luke Lango, InvestorPlace Senior Investment Analyst Jul 1, 2021

Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy.

7 CRISPR Stocks for the Future of Medicine

By Luke Lango, InvestorPlace Senior Investment Analyst Jan 15, 2021

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century.

There's a Lot of Upside For Emerging Gene-Editing Companies

From MarketBeat Feb 21, 2023

These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come.

Cellectis stock plunges ~17% after hours on $22M ADS offering (NASDAQ:CLLS)

From Seeking Alpha Feb 2, 2023

Cellectis (CLLS) on Thursday launched a global offering of USD22 million of its American Depositary Shares.

CLLS stock rises as terms of Cytovia licensing deal change (NASDAQ:CLLS)

From Seeking Alpha Jan 23, 2023

Cellectis S.A. (CLLS) added ~9% pre-market Monday after announcing changes to the certain financial terms of its partnership with Cytovia Therapeutics. Read the full story here.

Cellectis (NASDAQ:CLLS), Primera Therapeutics to collaborate

From Seeking Alpha Dec 29, 2022

Primera Therapeutics and French biotech Cellectis (CLLS) on Thursday said they would collaborate to develop therapies for mitochondrial diseases. Read more on the deal here.

Cellectis (NASDAQ:CLLS) to get €40M credit facility from European Investment Bank

From Seeking Alpha Dec 28, 2022

Clinical-stage biotech Cellectis (CLLS) on Wednesday said it had entered into a €40M credit agreement with the European Investment Bank. Read more on the agreement here.

Robert W. Baird Keeps Their Buy Rating on Cellectis SA (CLLS)

From TipRanks Dec 2, 2022

In a report released on November 30, Jack Allen from Robert W. Baird maintained a Buy rating on Cellectis SA (CLLS – Research Report), with a price...

Cellectis S.A. ADR (CLLS)

7 CRISPR Stocks With the Best Long-Term Potential

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

7 Gene Editing Stocks Promising to Change our DNA

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Cellectis S.A. ADR (CLLS)

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

CLLS Stock Predictions, Articles, and Cellectis S.A. ADR News

Subscriber Sign in